Thomas Jefferson University

The Texas A&M University System

Temple Therapeutics, Inc.

Drexel University

Scott & White Healthcare

University of Medicine and Dentistry of New Jersey

Other

Fibrogen, Inc.

University of Liège

Tulane University

Tulane University Health Sciences Center

Mcp Hahnemann University

Cp Hahnemann University

Universitéde Liége

Darwin J. Prockop

Darwin J Prockop

Robert Rosa

Gavin W Roddy

Leena M Ala-Kokko

Barry A Berkowitz

Aleksander Sieron

Joo Youn Oh

Andrzej Fertala

Shi-Wu Li

Yoshio Hojima

Ruth F Pereira

Kari I Kivirikko

Dale L Woodbury

Jaspal S Khillan

Ira B Black

Emily Schwarz

Alain Colige

David Colter

Dennis B Leeper

Gerardus C Tromp

Clinton T Baldwin

Michael D O'Hara

Amy Geddis

Pertti Ritvaniemi

Renato L Baserga

James M Early

Michael Pack

Loretta D Spotila

Taina Pihlajaniemi

Weiwen Deng

Ichiro Sekiya

Carl A Gregory

Philipp Vandenberg

Heikki Helminen

Boris Sokolov

Nilofer Nina Ahmad

Ian Hopkinson

Donald Phinney

Charlene J Williams

Matthew J Rock

David G Stokes

Paul Nugent

Hidetaka Nishida

S Ausim Azizi

Qingguo Zhao

Askok K Shetty

Charles M Lapiere

Andrea Westerhausen Larson

RyangHwa Lee

Carl Gregory

Constantinos D Deltas

Jarmo K&ouml;rkk&ouml;

Jeffrey Spees

Susanna Annunen

Mirko Vuoristo

Kathy K H Svoboda

Jason Smith

Larisa Sereda

Sirpa Kontusaari

Petteri Paassilta

Radhika Pochampally

Tero Pihlajamaa

Stacy Renay Beltran

S Helena Kuivaniemi

Anne Olsen

Joseph Kulkosky

Fei Liu

Arupa Ganguly

Alexey Laptev

Sirpa I Kontusaari

Carla DiGirolamo

Dong-Ki Kim

James J Earley

Sisko H Kuivaniemi

Ryang Hwa Lee

Charles Lapiere

Leena Ala-Kokko

Jimin Yu

Preparations comprising an enriched population of extracellular vesicles (nEVs) having a negatively charged surface, and that are CD81+ and CD9&#x2212;, are provided. Improved processes and methods for producing an enriched population of nEVs from non-murine cells, especially human origin cells and/or tissues, are disclosed. Therapeutic methods for using the preparations, including for reducing brain inflammation and treatment of various pathologies associated with brain inflammation, such as by intravenous or intranasal administration, are also described. Methods and preparations for reducing brain inflammation associated with traumatic brain injury (TBI) are also disclosed. A method for treating a patient having suffered a mild traumatic injury (mTMI), or concussion, such as a sports-related head injury, is also disclosed. The nEVs are also demonstrated to reduce the expression level of IL-I&#x3b2; in brain tissue of an animal having had traumatic brain injury. Methods for improving cognitive function and performance in animals after a traumatic brain injury is also demonstrated using the preparations of nEVs disclosed herein.

Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof

A method of producing mesenchymal stem cells from induced pluripotent stem cells in which induced pluripotent stem cells are cultured in the presence of a TGF-&#x3b2; inhibitor an in an atmosphere containing from about 7 vol. % to about 8 vol. % COfor a period of time from about 20 day to about 35 days. The cells then are transferred to a culture dish having a hydrophilic surface, and the cells are cultured in a medium containing a TGF-&#x3b2; inhibitor for a period of time sufficient to produce mesenchymal stem cells. Such mesenchymal stem cells are more stable and less likely to form tumors, cancers, or teratomas. Also, the induced pluripotent stem cells may be genetically engineered with at least one polynucleotide encoding a therapeutic agent and then are cultured as hereinabove described to provide genetically engineered mesenchymal stem cells that express sustained amounts of a biologically active protein or polypeptide.

Mesenchymal stem cells derived from induced pluripotent stem cells

The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases

The present invention provides compositions comprising mesenchymal stem cells (MSCs), and methods for their novel use in the repair of cardiac damage and treatment of inflammatory diseases. The invention also provides methods for using TSG-6 protein that is secreted by MSCs under certain conditions, for repair of cardiac damage and inflammatory disease. The compositions of the invention may be particularly useful in restoring cardiac function following cardiac damage, including, but not limited to, myocardial infarction, as well as in reducing symptoms of inflammatory disease.

Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage

A method of treating or preventing a gum disease or gum disorder or gum injury in a mammal by administering to the mammal at least one inflammation modulatory or anti-inflammatory protein or polypeptide, such as TSG-6 protein, or a biologically active fragment, derivative, or analogue thereof. Gum diseases or gum disorders or gum injuries that may be treated include periodontal gum disease, and gum wounds resulting from gum surgeries.

Treatment of gum diseases and gum disorders with TSG-6 protein

The present invention encompasses an osteogenic composition comprising mesenchymal stem cells pre-cultured in the presence of an agent that accelerates canonical Wnt signaling therein. Also, provided are osteogenic compositions incorporated into a biocompatible gel. The present invention provides methods for treating bone degeneration or injury associated with a pathophysiological condition in a mammal or for accelerating repair of a skeletal injury in a mammal by administering to the mammal or contacting the site of injury with the osteogenic composition.

Compositions of mesenchymal stem cells to regenerate bone

The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.

Stanniocalcin-1 (STC-1) therapy for treatment of retinal diseases

Protein therapy for treatment of retinal diseases

Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration

The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.

Differentiation of bone marrow cells into neuronal cells and uses therefor

The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels of cyclic AMP. Methods for treating a human patient in need of neural cells are also disclosed, as well as methods for treating a human patient having a disease, condition, or disorder of the central nervous system.

Directed in vitro differentiation of marrow stromal cells into neural cell progenitors

Growing community of inventors

Philadelphia, PA, United States of America

Darwin J Prockop